Low-dose buprenorphine initiation in the era of fentanyl and fentanyl analogs: A case series of outpatient inductions

J Opioid Manag. 2023 Sep-Oct;19(5):455-460. doi: 10.5055/jom.0819.

Abstract

Buprenorphine, a partial opioid agonist, is a Food and Drug Administration-approved medication for the treatment of opioid use disorder (OUD). However, due to its high binding affinity, precipitated withdrawal may occur if initiated in the presence of other opioids. The growing literature demonstrates promise for alternative induction model of low-dose initiation of buprenorphine for the treatment of OUD, specifically targeting patients averse to withdrawal or using fentanyl. In this case series, we present four clinical cases of outpatient inductions, in which three out of four successfully transitioned from fentanyl to buprenorphine, and one patient transitioned from methadone to buprenorphine using a low-dose induction method.

MeSH terms

  • Analgesics, Opioid / adverse effects
  • Buprenorphine* / therapeutic use
  • Fentanyl / therapeutic use
  • Humans
  • Methadone / therapeutic use
  • Opiate Substitution Treatment
  • Opioid-Related Disorders* / diagnosis
  • Opioid-Related Disorders* / drug therapy
  • Outpatients

Substances

  • Buprenorphine
  • Analgesics, Opioid
  • Fentanyl
  • Methadone